Stocks and InvestingStocks and Investing
Thu, September 23, 2021
Wed, September 22, 2021
Tue, September 21, 2021
Mon, September 20, 2021
Fri, September 17, 2021
Thu, September 16, 2021

Vikram Purohit Maintained (TBPH) at Sell with Decreased Target to $10 on, Sep 16th, 2021


Published on 2024-10-27 17:55:27 - WOPRAI, Vikram Purohit
  Print publication without navigation


Vikram Purohit of Morgan Stanley, Maintained "Theravance Biopharma, Inc." (TBPH) at Sell with Decreased Target from $14 to $10 on, Sep 16th, 2021.

Vikram has made no other calls on TBPH in the last 4 months.



There are 2 other peers that have a rating on TBPH. Out of the 2 peers that are also analyzing TBPH, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021


This is the rating of the analyst that currently disagrees with Vikram


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021